- Current report filing (8-K)
20 January 2010 - 3:33AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
Current
Report Pursuant to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
January
19, 2010
Date of
Report (Date of earliest event reported)
OSI PHARMACEUTICALS,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
0-15190
|
|
13-3159796
|
(State or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
41
Pinelawn Road
(Address
of principal executive offices)
(631)
962-2000
(Registrant's
telephone number, including area code)
N/A
(Former
name or former address,
if
changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨
|
Written
communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 8.01. Other
Events.
On
January 15, 2010, OSI Pharmaceuticals, Inc. (“OSI”) and Genentech, Inc., a
wholly owned member of the Roche Group, announced that the U.S. Food and Drug
Administration has extended the review period for the supplemental New Drug
Application for Tarceva® (erlotinib) as a first-line maintenance therapy in
advanced non-small cell lung cancer. A copy of OSI’s press
release, dated January 15, 2010, is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01.
Financial Statements and Exhibits.
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated January 15,
2010.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: January 19, 2010
|
OSI PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Barbara A. Wood
|
|
|
Barbara A. Wood
|
|
|
Senior Vice President, General Counsel
|
|
|
and Secretary
|
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated January 15,
2010.
|
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Osi Pharmaceuticals Inc. (MM) (NASDAQ): 0 recent articles
More News Articles